Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 18;10(2):346.
doi: 10.3390/jcm10020346.

Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study

Affiliations

Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study

Giovanni Tarantino et al. J Clin Med. .

Abstract

Among risk factors (apart from smoking) likely involved in bladder cancer (BCa), metabolic syndrome (MS), obesity and type 2 diabetes mellitus (T2DM) have been explored with contrasting results. In spite of these studies, there is little data on the association between nonalcoholic fatty liver disease (NAFLD), its main driver, i.e., insulin resistance (IR), and BCa. Implanting a cross-sectional retrospective study we tried to investigate both NAFLD and IR prevalence in a hospital based population of BCa patients. We studied laboratory data from 204 patients with histologically confirmed non metastatic BCa and 50 subjects with no BCa, but with bladder diseases (no Ca BD). We evaluated the presence of NAFLD by the triglycerides/glucose Index (TyG Index), using a cut-off of 0.59 and by the Aspartate Aminotransferase/Alanine Aminotransferase AST/ALT ratio. IR was assessed by the same TyG Index (cut-off 4.68) and the triglycerides/High-Density Lipoprotein HDL ratio (cut-off 2.197). The diagnosis of impaired fasting glucose (IFG), condition of prediabetes, as well as that of T2DM was assessed according to canonical guidelines. The TyG Index predicted NAFLD presence in both groups (p = 0.000), but the BCa group showed a major percentage of NAFLD cases with respect to no Ca BD group (59% versus 40%). A greater proportion of IR (47%) in BCa group than in no Ca BD one (37%) was evidenced by the TyG Index with its median value significantly different (p = 0.0092). This high rate of IR in the BCa group was confirmed by the triglycerides/HDL ratio (p = 0.02). Prediabetes and T2DM were more prevalent in the BCa group than no Ca BD group (p = 0.024). In this study a consistent NAFLD presence was found in BCa patients. This is an important comorbidity factor that deserves further consideration in prospective studies. The higher prevalence of NAFLD, IR, prediabetes and T2DM in the BCa group evidences the need that these disorders should be reckoned as adjunct factors that could impact on this cancerous disease.

Keywords: NAFLD; bladder cancer; impaired fasting glucose; insulin resistance; no cancerous bladder diseases; prediabetes; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Behaviour of the TyG Index in both groups. TyG Index, triglycerides/glucose index; BCa, bladder cancer; no Ca BD, no cancerous bladder diseases/urinary conditions. There are two outliers among BCa group.
Figure 2
Figure 2
Prediction of the TyG Index by the triglycerides/HDL ratio. TyG Index, triglycerides/glucose index. HDL, high density lipoprotein. There are only two outliers.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Sun M., Trinh Q.-D. Diagnosis and staging of bladder cancer. Hematol. Oncol. Clin. North Am. 2015;29:205–218. doi: 10.1016/j.hoc.2014.10.013. - DOI - PubMed
    1. Cantiello F., Cicione A., Salonia A., Autorino R., De Nunzio C., Briganti A., Gandaglia G., Dell’Oglio P., Capogrosso P., Damiano R. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review. Int. J. Urol. 2015;22:22–32. doi: 10.1111/iju.12644. - DOI - PubMed
    1. Stocks T., Bjørge T., Ulmer H., Manjer J., Häggström C., Nagel G., Engeland A., Johansen D., Hallmans G., Selmer R., et al. Metabolic risk score and cancer risk: Pooled analysis of seven cohorts. Int. J. Epidemiol. 2015;44:1353–1363. doi: 10.1093/ije/dyv001. - DOI - PMC - PubMed
    1. Montella M., Di Maso M., Crispo A., Grimaldi M., Bosetti C., Turati F., Giudice A., Libra M., Serraino D., La Vecchia C., et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: A case-control study. BMC Cancer. 2015;15:720. doi: 10.1186/s12885-015-1769-9. - DOI - PMC - PubMed

LinkOut - more resources